Literature DB >> 131986

Inhibition of plasmin by normal and antiplasmin-depleted human plasma.

J Edy, F De Cock, D Collen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 131986     DOI： 10.1016/0049-3848(76)90229-2

Source DB:  PubMed          Journal:  Thromb Res        ISSN： 0049-3848            Impact factor:   3.944


× No keyword cloud information.
  8 in total

1.  A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo.

Authors:  M S Runge; T Quertermous; P J Zavodny; T W Love; C Bode; M Freitag; S Y Shaw; P L Huang; C C Chou; D Mullins
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

2.  Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo.

Authors:  M S Runge; C Bode; G R Matsueda; E Haber
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

3.  Influence of the fast-acting inhibitor of plasminogen activator on in vivo thrombolysis induced by tissue-type plasminogen activator in rabbits. Interference of tissue-derived components.

Authors:  M Colucci; J A Paramo; J M Stassen; D Collen
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

Review 4.  Mechanisms of deep vein thrombosis: a review.

Authors:  M Brozović
Journal:  J R Soc Med       Date:  1979-08       Impact factor: 5.344

5.  Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis.

Authors:  C Korninger; O Matsuo; R Suy; J M Stassen; D Collen
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

6.  Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.

Authors:  D Collen; J M Stassen; M Verstraete
Journal:  J Clin Invest       Date:  1983-02       Impact factor: 14.808

7.  The behavior of alpha2-plasmin inhibitor in fibrinolytic states.

Authors:  N Aoki; M Moroi; M Matsuda; K Tachiya
Journal:  J Clin Invest       Date:  1977-08       Impact factor: 14.808

8.  Antithrombin III, plasminogen and alpha 2 antiplasmin in jaundice. Clinical usefulness and prognostic significance.

Authors:  J J Rodzynek; D Urbain; P Leautaud; P Wettendorff; A Delcourt
Journal:  Gut       Date:  1984-10       Impact factor: 23.059
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.